↓ Skip to main content

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Overview of attention for article published in Journal of Clinical Oncology, January 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
13 news outlets
twitter
50 X users
patent
3 patents
facebook
1 Facebook page
reddit
1 Redditor
guideline
1 clinical guideline source

Readers on

mendeley
319 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 50 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 319 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 319 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 38 12%
Student > Ph. D. Student 29 9%
Other 24 8%
Student > Bachelor 18 6%
Student > Doctoral Student 17 5%
Other 50 16%
Unknown 143 45%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 71 22%
Biochemistry, Genetics and Molecular Biology 46 14%
Pharmacology, Toxicology and Pharmaceutical Science 11 3%
Immunology and Microbiology 10 3%
Unspecified 7 2%
Other 27 8%
Unknown 147 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 125. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2026.
All research outputs
#421,824
of 34,324,933 outputs
Outputs from Journal of Clinical Oncology
#811
of 32,274 outputs
Outputs of similar age
#9,829
of 588,341 outputs
Outputs of similar age from Journal of Clinical Oncology
#13
of 327 outputs
Altmetric has tracked 34,324,933 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,274 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 588,341 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 327 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.